GABAeron, Inc.

San Francisco, CA · Biotech · Private

Small molecule therapeutics that protect GABAergic neurons from apoE-induced damage in Alzheimer's disease

Grants
$5.7M
6 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4$292,422
Federal grantDepartment of Health and Human Services · Phase I · Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease$342,592
Federal grantDepartment of Health and Human Services · Phase II · Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4$1,930,668
Federal grantDepartment of Health and Human Services · Phase II · Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease$1,079,582
Federal grantDepartment of Health and Human Services · Phase II · Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4$948,584
Federal grantDepartment of Health and Human Services · Phase II · Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease$1,086,082
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2605CONCARLO HOLDINGS, LLC—$450K
2606GSNO THERAPEUTICS, INC.——
2607ANEURYST, INC.——
2608GABAeron, Inc.——
2609Curza Inc—$367K
2610BreStem Therapeutics, Inc.—$300K
2611VERAMORPH LLC—$262K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.